Michael Ulz
Stock Analyst at Morgan Stanley
(4.51)
# 263
Out of 5,090 analysts
103
Total ratings
54.84%
Success rate
27.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $7.89 | +216.86% | 3 | Dec 4, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $45 → $48 | $61.23 | -21.61% | 6 | Nov 26, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $81.40 | +15.48% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $39.24 | +159.94% | 4 | Oct 23, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $75 → $81 | $69.35 | +16.81% | 4 | Oct 16, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $5.81 | +261.45% | 8 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $405 → $475 | $456.99 | +3.94% | 12 | Oct 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $6.87 | +263.90% | 12 | May 9, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.58 | +752.71% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $13.26 | +118.70% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $2.23 | +796.86% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $2.08 | +381.93% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $54.41 | +76.44% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $20.68 | +151.45% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.08 | +550.13% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $11.34 | +138.10% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $2.10 | +852.38% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.33 | +1,251.35% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.72 | +1,288.89% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $5.23 | -42.58% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $6.40 | +368.75% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $27.86 | +1,694.69% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $36.92 | +116.68% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $9.94 | +50.98% | 3 | Jul 12, 2017 |
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $7.89
Upside: +216.86%
Arrowhead Pharmaceuticals
Nov 26, 2025
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $61.23
Upside: -21.61%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $81.40
Upside: +15.48%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $39.24
Upside: +159.94%
Mirum Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $75 → $81
Current: $69.35
Upside: +16.81%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $5.81
Upside: +261.45%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Equal-Weight
Price Target: $405 → $475
Current: $456.99
Upside: +3.94%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.87
Upside: +263.90%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.58
Upside: +752.71%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $13.26
Upside: +118.70%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.23
Upside: +796.86%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $2.08
Upside: +381.93%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $54.41
Upside: +76.44%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $20.68
Upside: +151.45%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.08
Upside: +550.13%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $11.34
Upside: +138.10%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $2.10
Upside: +852.38%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.33
Upside: +1,251.35%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.72
Upside: +1,288.89%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $5.23
Upside: -42.58%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $6.40
Upside: +368.75%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $27.86
Upside: +1,694.69%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $36.92
Upside: +116.68%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $9.94
Upside: +50.98%